Hostname: page-component-74656f9884-2dmjx Total loading time: 0 Render date: 2026-11-07T09:24:16.551Z Has data issue: false hasContentIssue false

A review of 733 published trials on Bio-Mos®, a mannan oligosaccharide, and Actigen®, a second generation mannose rich fraction, on farm and companion animals.

Published online by Cambridge University Press:  20 May 2015

P. Spring
Affiliation:
Bern University of Applied Sciences, Bern, Switzerland
C. Wenk
Affiliation:
Institute for Animal Science, ETH Zurich, Switzerland
A. Connolly*
Affiliation:
Alltech Inc, Lexington KY, USA
A. Kiers
Affiliation:
Kiers Consulting, Washington DC, USA
*
*Corresponding author:aconnolly@alltech.com
Rights & Permissions [Opens in a new window]

Summary

Mannan-oligosaccharides (MOS), as zootechnical feed ingredients, are widely used in animal nutrition. MOS has been commercially available since the launch of Bio-Mos® in the early 1990's and has a substantial body of scientific papers and practical examples of its efficacy. Since 1999, the use of MOS in animal feed has become more prominent, mainly due to the European ban on prophylactic antibiotic growth promoters in animal feed. MOS, with its ability to bind and limit the colonisation of gut pathogens, has proven to be an effective solution for antibiotic-free diets, as well as providing support for immunity and digestion. MOS has been shown to improve gastrointestinal health, thus improving wellbeing, energy levels and performance. Most MOS products, particularly those that have been scientifically developed, derive from the cell wall of the yeast, Saccharomyces cerevisiae. In 2009, a mannose-rich fraction (MRF) product was commercially launched as a ‘second generation’ of these MOS-type products, with enhanced activities in immune modulation and intestinal health. The purpose of this paper is to review the existing data on the benefits of MOS for all species of animals, discuss its mechanisms of action in vivo and compare the benefits of using second generation MRF to original MOS.

Information

Type
Review Article
Copyright
Copyright © Cambridge University Press and Journal of Applied Animal Nutrition Ltd. 2015 
Figure 0

Figure 1. Blocking bacterial attachment and thus inhibiting host colonisation by MOS

Figure 1

Figure 2. Villi without MOS supplementation (left) and villi with MOS supplementation (right). Pictures courtesy of S. Collett, University of Georgia, USA

Figure 2

Figure 3. Structure of small intestine

Figure 3

Table 1. Influence of feeding MOS in diets on mare IgA immunity (Ott 2006).

Figure 4

Figure 4. Number of circulating active neutrophils (O'Carra 2007) measured as the number of active neutrophils per microscope field (x40)

Figure 5

Table 2. Body weight gain, feed conversion ratio, and mortality of rabbits fed a control diet or one supplemented with MOS.

Figure 6

Table 3. Metanalysis of broiler trials showing average responses to MOS supplementation (Hooge, 2004a).

Figure 7

Table 4. Average responses to MOS supplementation in turkey diets (Hooge, 2004)

Figure 8

Table 5. Equations for 33 (24 for mortality) trial results investigating the influence of MOS in feed on performance parameters of growing turkeys (P < 0.05) (Rosen, 2007b).

Figure 9

Table 6. Metanalysis of impact of feeding MOS to growing pigs (Miguel, 2004).

Figure 10

Table 7. Metanalysis of benefits in calf performance from feeding MOS (Hooge, 2006).

Figure 11

Table 8. Comparison of some meta-analyses involving MOS (Bio-Mos®) and MRF (ActigenTM) on broiler growth performance.